Targeted prostate cancer treatment cuts risk of side effects, study suggests

• Focal therapy for prostate cancer demonstrates reduced side effects compared to whole-gland treatments, based on a decade-long NHS trial of 3,500 men, supporting its use as a tissue-sparing alternative.
• Long-term safety and efficacy data from this substantial cohort provides robust evidence for considering focal therapy in appropriate patient selection and informed consent discussions.
• The 10-year follow-up period establishes sufficient durability data to inform treatment planning, though individual patient factors and tumour characteristics remain essential for determining candidacy.

An NHS trial over 10 years followed nearly 3,500 men who received focal therapy, a less invasive treatment.

ClinicaliQ summarises and contextualises external updates for clinical awareness, then links to the original publisher for the full article and most current context.